PDCD1 and non-small cell lung carcinoma: PD-1 blockage given prior to surgical removal of NSCLC is safe and induced a major pathological response (MPR) in 45% of resected tumors, according to the first neoadjuvant immunotherapy trial for patients with early-stage lung cancer [5].